Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 30Terminated 15Recruiting 8Unknown 4Active not recruiting 4Not yet recruiting 3Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 1FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Other hematologic neoplasm 4Myeloid 1

Conditions

Leukemia, Myeloid, Acute 28Myelodysplastic Syndromes 10Recurrence 5Leukemia, Myelomonocytic, Chronic 4Leukemia 4Lymphoma, T-Cell, Peripheral 3Lymphoma, Large B-Cell, Diffuse 2Lymphoma, Extranodal NK-T-Cell 2Hematologic Neoplasms 2Neoplasm, Residual 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myeloid 1Glioma 1Frailty 1Burkitt Lymphoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 35Cyclophosphamide 26Etoposide 18Radiotherapy 16Daunorubicin 16Busulfan 15Peripheral Blood Stem Cell Transplantation 14Methotrexate 14Idarubicin 14Mercaptopurine 12Dexamethasone 12Vincristine 11Thioguanine 9Mitoxantrone 9Doxorubicin 8Asparaginase 8Antilymphocyte Serum 8pegaspargase 7fludarabine phosphate 7Prednisolone 7Polymerase Chain Reaction 7Filgrastim 7Cyclosporine 7Prednisone 6Mycophenolic Acid 5Melphalan 5Leucovorin 5Gene Expression Profiling 5Vindesine 4N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Leukemia × Azacitidine × Clear all
NCT03825367 2022-10-12

Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1/2 Unknown
13 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT04722952 2021-12-03

PD-1 Inhibitor Combined With Azacytidine and Homoharringtonine,Cytarabine, G-CSF for Refractory or Relapsed AML

The First Affiliated Hospital of Soochow University

Phase 3 Unknown
30 enrolled
Other hematologic neoplasm

Leukemia, Recurrence, Leukemia, Myeloid, Acute

NCT05061147 2021-10-01

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Max-40279-01 in Combination With Azacitidine (AZA) in Patients With Myelodysplastic Syndrome (MDS) or Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Maxinovel Pty., Ltd.

Phase 1/2 Unknown
100 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00728520 2008-08-06

Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy

Kansas City Veteran Affairs Medical Center

Phase 2 Unknown
40 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon ⚡